Literature DB >> 23859338

Prevalence gradients of Friedreich's ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge.

Pierre Vankan1.   

Abstract

Combining data from epidemiological studies in Friedreich's Ataxia (FRDA) and patient organization membership lists, shows that FRDA prevalence exhibits large regional differences in Europe with a prevalence gradient from west to east. Highest levels are observed in northern Spain, south of France and Ireland, lowest levels in Scandinavia and Russia. The observed distribution of FRDA in Europe co-localizes with the gradient of the chromosomal R1b marker as detected within west Europe. This gradient is either derived from Palaeolithic migrations out of the Franco-Cantabrian Ice age refuge or from Neolithic migrations entering west Europe with the advance of agriculture. FRDA prevalence may have been increased in this population anytime after its separation from the closely related R1a carrying group. East European populations with a high frequency of the R1a marker show 10 fold lower prevalence of FRDA, indicating that the FRDA mutation was present in the common ancestor and was increased in the R1b carrying group. The FRDA carrying population went through a Palaeolithic population bottleneck supporting the view that the observed FRDA distribution and potentially the R1b distribution are derived from Palaeolithic migrations out of the Franco-Cantabrian ice age refuge.
© 2013 International Society for Neurochemistry.

Entities:  

Keywords:  Friedreich's Ataxia; Palaeolithic origin; R1b haplotype; prevalence in Europe

Mesh:

Year:  2013        PMID: 23859338     DOI: 10.1111/jnc.12215

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  25 in total

1.  Frataxin deficiency impairs mitochondrial biogenesis in cells, mice and humans.

Authors:  Mittal J Jasoliya; Marissa Z McMackin; Chelsea K Henderson; Susan L Perlman; Gino A Cortopassi
Journal:  Hum Mol Genet       Date:  2017-07-15       Impact factor: 6.150

2.  Health-related quality of life and depressive symptoms in Friedreich ataxia.

Authors:  Javier Pérez-Flores; Atteneri Hernández-Torres; Fernando Montón; Antonieta Nieto
Journal:  Qual Life Res       Date:  2019-09-28       Impact factor: 4.147

3.  Application of Quantitative Motor Assessments in Friedreich Ataxia and Evaluation of Their Relation to Clinical Measures.

Authors:  Christian Hohenfeld; Imis Dogan; Robin Schubert; Claire Didszun; Ludger Schöls; Matthis Synofzik; Ilaria A Giordano; Thomas Klockgether; Jörg B Schulz; Ralf Reilmann; Kathrin Reetz
Journal:  Cerebellum       Date:  2019-10       Impact factor: 3.847

Review 4.  Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders.

Authors:  Sweta Shah; Marc Marie Dooms; Sofia Amaral-Garcia; Mariana Igoillo-Esteve
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

Review 5.  Discovery of Therapeutics Targeting Oxidative Stress in Autosomal Recessive Cerebellar Ataxia: A Systematic Review.

Authors:  Sze Yuen Lew; Michael Weng Lok Phang; Pit Shan Chong; Jaydeep Roy; Chi Him Poon; Wing Shan Yu; Lee Wei Lim; Kah Hui Wong
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-19

6.  Friedreich Ataxia: Diagnostic Yield and Minimal Frequency in South Brazil.

Authors:  Helena Fussiger; Maria Luiza Saraiva-Pereira; Sandra Leistner-Segal; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2019-02       Impact factor: 3.847

7.  The first biallelic missense mutation in the FXN gene in a consanguineous Turkish family with Charcot-Marie-Tooth-like phenotype.

Authors:  Ayşe Candayan; Gulshan Yunisova; Arman Çakar; Hacer Durmuş; A Nazlı Başak; Yeşim Parman; Esra Battaloğlu
Journal:  Neurogenetics       Date:  2019-10-31       Impact factor: 2.660

8.  Dysphagia and swallowing-related quality of life in Friedreich ataxia.

Authors:  Adam P Vogel; Sophie E Brown; Joanne E Folker; Louise A Corben; Martin B Delatycki
Journal:  J Neurol       Date:  2013-12-27       Impact factor: 4.849

9.  Dimethyl fumarate dose-dependently increases mitochondrial gene expression and function in muscle and brain of Friedreich's ataxia model mice.

Authors:  Chun Kiu Hui; Elena N Dedkova; Claire Montgomery; Gino Cortopassi
Journal:  Hum Mol Genet       Date:  2021-02-25       Impact factor: 5.121

Review 10.  Friedreich's ataxia: clinical features, pathogenesis and management.

Authors:  A Cook; P Giunti
Journal:  Br Med Bull       Date:  2017-12-01       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.